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ABSTRACT
The present study sought to investigate the risk factors for physical disability upon 
release from multidrug therapy (MDT) in new cases of leprosy, registered at a referral 
center in Brazil. This is a longitudinal and retrospective study that evaluated 260 patients. 
Multivariate analyses, using both the ordinal logistic regression, as well as the classification 
and regression tree (CART) algorithm were performed to determine the factors associated 
with physical disability upon release from treatment. The prevalence of disability did not 
differ significantly between diagnosis and release from treatment. Number of affected nerves 
and sensory impairment upon diagnosis were risk factors for disability at the end of MDT. 
The analysis using the CART algorithm resulted in the development of a clinical score to 
predict the risk of disability upon release from MDT. The decision tree may have a direct 
applicability in clinical practice for professionals dealing with leprosy, as it allows them to 
identify patients with a higher risk of physical disability through the use of simple and widely 
available clinical tests. This study also shows that the disability grade upon admission is 
the main risk factor for disability upon release from MDT. This result draws attention to the 
importance of early diagnosis in disability prevention.
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INTRODUCTION
Leprosy is a chronic granulomatous infectious disease caused by the intracellular 
bacterium Mycobacterium leprae, which affects the skin and peripheral nerves1,2. 
It is the main infectious cause of disability and peripheral neuropathy in the world, 
presenting a greater importance in developing countries, where it is endemic2,3. 
Neuropathy is the most serious manifestation of the disease, as it can lead to 
impairments and disabilities. These are crucial elements that differentiate leprosy 
from other diseases given that it has great physical, psychological and social 
implications4,5.
In 2016, 12,437 new cases of leprosy with grade 2 disabilities (G2D) were reported 
globally, corresponding to 1.7 per million people. Although it represents a 12% 
reduction in the number of new G2D cases, when compared to 14,284 cases detected 
in 2015, some countries detected more new G2D cases in 2016 than in 20156. Except 
for the year 2016, the number of new G2D cases has remained constant over the past 
ten years, within the range of 13,000 to 14,000, indicating a stagnation in leprosy 
control7. Due to the magnitude of the problem, the World Health Organization (WHO) 
launched in 2016 a 5-year global leprosy strategy to reduce the burden of disease. The 
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strategy set three main targets to be achieved at global level 
by 2020: reduction of new G2D cases in children to zero, a 
reduction in the rate of new G2D cases to less than 1 case 
per million people and zero countries with laws that allow 
discrimination against leprosy6.
To treat leprosy properly, it is necessary to have 
an in-depth knowledge of its epidemiology and the 
determining factors of disability5,8. Stagnation in the 
control of leprosy, especially in the number of new cases 
with grade 2 disabilities, emphasizes the need for further 
research on preventive measures7. More evidence of 
risk factors for nerve function impairment is important 
to prioritize the follow-up of high-risk patients and to 
develop disability prevention strategies9. Various studies 
have identified factors associated with physical disability 
upon diagnosis, such as age, sex, classification, duration 
of disease, number of skin lesions, number of affected 
nerves and socioeconomic factors5,10. Studies that analyze 
risk factors for disabilities upon release from treatment are 
less common, especially in Brazil. As the epidemiology of 
the disease varies greatly worldwide, a certain population 
may present specific risk factors for disabilities, in addition 
to factors that are common to all populations. The present 
study aims to identify and quantify the factors associated 
with the presence of physical disability upon release from 
MDT in new cases of leprosy at a referral center in Brazil.
MATERIAL AND METHODS
Design
This is a longitudinal and retrospective study performed 
at Eduardo de Menezes Hospital (HEM), which is a public 
referral center in dermatology located in Belo Horizonte, 
Minas Gerais, Brazil. Clinical and sociodemographic 
information was collected from medical records and leprosy 
notification forms.
Study subjects and sample size
All new untreated cases of leprosy admitted to HEM for 
treatment over the period of 2005-2010 were eligible for this 
study. Patients who for any reason did not complete MDT 
at the referral center were later excluded. In the observed 
period, 342 new cases were reported. After analyzing 
the medical records, 82 patients were excluded (45 were 
transferred, 35 discontinued treatment and two died). 
Therefore, 260 new cases were included in the study.
As it was a convenience sample, the sample size 
calculation was not performed before the study. Considering 
the sensory impairment as the main factor to describe the 
grade of disability upon release from MDT, a sample of 260 
patients has a 99% power to detect the associations found 
at a significance level of 5%.
Procedures
The study procedures were part of the medical care 
routine of HEM. Upon admission, all patients were 
submitted to dermatoneurological examination, performed 
by a dermatologist, to confirm the diagnosis. Nerve function 
assessment was repeated every three months and upon 
release from MDT in asymptomatic patients. Nerve function 
was assessed monthly in patients with symptoms of neuritis 
or leprosy reactions, or under treatment for these conditions. 
The neurological examination followed recommendations 
set forth by the Brazilian Ministry of Health11.
Upon admission, skin smears were collected from all 
patients, in ear lobes, one skin lesion and one sample from 
the elbow. As recommended by the Brazilian Ministry 
of Health, patients received MDT according to their 
operational classification12.
The follow-up period of the study varied from six to 
nine months for paucibacillary cases (PB) and from 12 to 
18 months for the multibacillary cases (MB). MB patients 
treated with alternative regimens without rifampicin were 
followed-up for 24 to 36 months.
Variables
The explanatory variables in the analyses included: 
age, gender, origin, schooling, method of case detection, 
number of skin lesions, number of affected nerves, type 
of neural alteration, operational classification, Madrid 
classification, bacteriological index (BI), leprosy reactions, 
type of treatment and disability grade upon diagnosis. The 
response variable was the disability grade upon release from 
MDT. All the explanatory variables, with the exception 
of reactions, were assessed at the time of diagnosis. The 
occurrence of leprosy reactions was investigated during the 
entire follow-up period.
Nerves were considered to be affected in the presence of 
nerve enlargement and/or sensory impairment and/or motor 
impairment. Sensory impairment was defined as a lack of 
response to 0.2 g monofilament (blue) on the hands and to 2.0 g 
(purple) on the feet. These reference values were based on a 
Nepalese study that assessed the touch sensibility in healthy 
volunteers13. Motor impairment was defined as any reduction 
in strength identified in the voluntary muscle testing.
The Madrid Classification was used to determine the 
clinical forms. For the operational classification, the number 
of skin lesions and BI were used. Patients with up to five 
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lesions were classified as PB and patients with six lesions 
or more as MB. In addition, all cases with positive BI were 
classified as MB12.
Type 1 or 2 reactions were diagnosed when in the 
presence of reactional skin lesions, accompanied or not by 
evidence of neuritis. Nerve function impairment, with or 
without pain or nerve tenderness, and without other reaction 
symptoms, was classified as isolated neuritis.
Regarding treatment, MDT/PB and MDT/MB were 
categorized as standard MDT regimens. Therapeutic 
schemes substituting at least one of the drugs were classified 
in the same category: alternative MDT regimens.
The maximum disability grade was assessed upon 
admission and release from MDT, as recommended by 
the Brazilian Ministry of Health12. Grade 1 disability was 
defined as the inability to feel the 2 g monofilament on the 
hands and feet, or the lack of immediate blinking in the eye 
exam using dental floss. Grade 2 disability was defined as 
the presence of one or more of the following alterations: 
lagophthalmos, ectropion, trichiasis, corneal opacity, a 
central visual acuity of less than 0.1 or an inability to count 
fingers at six meters, trophic and/or traumatic lesions on 
hands or feet, claws, absorptions, wrist drop, foot drop and 
ankle contractures12.
Statistical analyses
The marginal homogeneity test was used to compare 
the disability grade upon diagnosis and release from 
treatment. In the univariate analyses, Pearson’s chi-
squared test or Fisher’s exact test were used to compare 
the categorical variables, while the Kruskal-Wallis test was 
used to analyze the numerical variables. Non-parametric 
tests were used due to the asymmetric character of the 
analyzed variables.
For the multivariate analysis, an ordinal logistic 
regression model was used14. The variables with a p-value 
below 0.20 in the univariate analysis were included in 
the multivariate model. In the final model, the significant 
variables remained within the 5% significance level. A 
multivariate analysis was also performed by means of a 
decision tree, using the Classification and Regression Tree 
(CART) algorithm15. In this analysis, an improvement of 
at least 0.01 was used as a stop criterion. SPSS 15.0 and 
STATA 10.0 were used for statistical analysis.
Ethical approval
The study was approved by the Research Ethics 
Committee of Eduardo de Menezes Hospital, where 
the study was conducted, and by the Research Ethics 
Committee of Federal University of Minas Gerais, for the 
master degree dissertation of one of the authors.
RESULTS
A total of 260 patients were included in this study, 138 
males (53.1%) and 122 females (46.9%), with an average 
age of 44 years upon diagnosis. One hundred and sixty 
three of the cases were multibacillary (62.7%) and the most 
common form of the disease was the borderline (54.6%). 
During the follow-up period, 29 patients (11.2%) presented 
a type 1 reaction, 48 (18.5%) with isolated neuritis and 
41(15.8%) presented a type 2 reaction. Upon diagnosis, 
nerve enlargement was observed in 70 (26.9%) of the cases, 
sensory impairment in 100 (38.5%), and motor impairment 
in 52 (20.0%), with the mean number of affected nerves 
reaching 2.5. 
Upon diagnosis, 56 patients (21.5%) presented grade 1 
disability, while 42 (16.2%) presented grade 2. The 
prevalence of disability did not differ significantly between 
diagnosis and release from treatment (Table 1). Among the 
260 patients, 255 had the disability grade evaluated upon 
release from MDT and, therefore, were included in the 
univariate and multivariate analyses.
The results of the univariate analysis for sociodemographic 
variables are illustrated in Table 2. The disability grade upon 
release from MDT was associated with schooling and the 
method of case detection (p-values <0.05). According 
to the univariate analysis, with the exception of the type 
of treatment, all clinical and quantitative variables were 
associated with the disability grade upon release from MDT 
(Tables 3 and 4).
In the multivariate analysis, the presence of sensory 
impairment upon diagnosis and the number of affected 
Table 1 - Comparison between the disability grade upon 
diagnosis and release from multidrug treatment (MDT) in new 
cases of leprosy reported at Eduardo de Menezes Hospital, 
2005-2010. 
N %
Disability grade upon diagnosis (n=260)
     Grade 0 
     Grade 1 
     Grade 2
162 
56 
42
62.3 
21.5 
16.2
Disability grade upon release from MDT (n=255)
     Grade 0 
     Grade 1 
     Grade 2
168 
41 
46
65.9 
16.1 
18.0
Note: n= number of cases. MDT- multidrug treatment; Marginal 
homogeneity test p-value = 0.297
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Table 2 - Univariate analysis of the association between sociodemographic variables and disability grade upon release from 
multidrug treatment (MDT) in new cases of leprosyreported at Eduardo de Menezes Hospital, 2005-2010.
Grade 0 Grade 1 Grade 2 p-value
Sex (n=255)
     Female 
     Male
84 (71.2%) 
84 (61.3%)
19 (16.1%) 
22 (16.1%)
15 (12.7%) 
31 (22.6%)
0.111*
Origin (n=227)
     Rural 
     Urban
5 (55.6%) 
143 (65.6%)
2 (22.2%) 
36 (16.5%)
 2 (22.2%) 
39 (17.9%)
0.679**
Schooling years (n=171)
     None 
     1 to 3  
     4 to 7  
     8 to 11  
     12 or more
5 (27.8%) 
23 (47.9%) 
46 (79.3%) 
33 (86.8%) 
8 (88.9%)
7 (38.9%) 
13 (27.1%) 
7 (12.1%) 
2 (5.3%) 
0 (0.0%)
6 (33.3%) 
12 (25.0%) 
5 (8.6%) 
3 (7.9%) 
1 (11.1%)
<0.001**
Method of case detection (n=251)
     Voluntary report 
     Referral 
     Contact
33 (76.7%) 
111 (61.3%) 
22 (81.5%)
7 (16.3%) 
28 (15.5%) 
4 (14.8%)
3 (7.0%) 
42 (23.2%) 
1 (3.7%)
0.020**
Note: * Chi-square test ** Fisherexact test; n = number of cases
Table 3 - Univariate analysis of the association between clinical variables and disability grade upon release from multidrug treatment 
(MDT) in new cases of leprosy reported at Eduardo de Menezes Hospital, 2005-2010.
Grade 0 Grade 1 Grade 2 p-value
Skin lesion count (n=250)
     1 
     2 to 5 
     ≥ 6
55 (90.2%) 
34 (75.6%) 
78 (54.2%)
3 (4.9%) 
6 (13.3%) 
30 (20.8%)
3 (4.9%) 
5 (11.1%) 
36 (25.0%)
<0.001*
Nerve enlargement (n=255)
     No 
     Yes
145 (78.0%) 
23 (33.3%)
25 (13.4%) 
16 (23.2%)
16 (8.6%) 
30 (43.5%)
<0.001*
Sensory impairment (n=255)
     No 
     Yes
142 (91.6%) 
26 (26.0%)
11 (7.1%) 
30 (30.0%)
2 (1.3%) 
44 (44.0%)
<0.001*
Motor impairment (n=255)
     No 
     Yes
160 (78.8%) 
8 (15.4%)
30 (14.8%) 
11 (21.2%)
13 (6.4%) 
33 (63.5%)
<0.000*
Madrid classification (n=255)
     Indeterminate 
     Tuberculoid 
     Borderline 
     Lepromatous
20 (100%) 
38 (90.4%) 
82 (58.6%) 
28 (52.8%)
0 (0.0%) 
2 (4.8%) 
29 (20.7%) 
10 (18.9%)
0 (0.0%) 
2 (4.8%) 
29 (20.7%) 
15 (28.3%)
<0.001**
Operational classification (n=255)
     Paucibacillary 
     Multibacillary
79 (84.9%) 
89 (54.9%)
7 (7.5%) 
34 (21.0%)
7 (7.5%) 
39 (24.1%)
<0.001*
Leprosy reactions (n=255)
     None 
     Neuritis only 
     Type 1 and 2 
     Type 1  
     Type 2
114 (86.4%) 
17 (35.4%) 
2 (33.3%) 
15 (53.6%) 
20 (48.8%)
9 (6.8%) 
11 (22.9%) 
1 (16.7%) 
10 (35.7%) 
10 (24.4%)
9 (6.8%) 
20 (41.7%) 
3 (50.0%) 
3 (10.7%) 
11 (26.8%)
<0.001**
Treatment (n=255)
     Standard MDT regimen 
     Alternative MDT regimen
140 (66.4%) 
28 (63.6%)
36 (17.1%) 
5 (11.4%)
35 (16.6%) 
11 (25.0%)
0.332*
Note: * Chi-square test ** Fisher exact test; n= number of cases
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nerves were the main factors associated with the disability 
grade determined upon release from MDT (Table 5). The 
model presented a good adjustment, according to Deviance 
statistics.
Factors associated with the disability grade upon release 
from MDT, according to the CART algorithm were the 
number of affected nerves, presence of sensory impairment 
and gender (Figure 1). The number of affected nerves upon 
admission was the main factor associated with the disability 
grade upon release from treatment. Patients with three or 
more affected nerves presented a 54.7% probability of 
having grade 2 disabilities by the end of the treatment. In 
this patients’ subgroup, it was also observed that when more 
than nine nerves were affected, this probability increased 
even further, reaching 95.7%. By contrast, patients with 
up to two nerves affected upon admission presented less 
chances of disability. To assess the disability risk in this 
subgroup of patients, the second important factor was 
sensory impairment upon diagnosis. The presence of this 
type of impairment increased the probability of grade 2 
disability from 1.3% to 11.1%. The male gender was the 
third factor associated with the presence of disability upon 
release from treatment in a small subgroup (patients with up 
to two affected nerves and with sensory impairment). The 
model presented good adjustment with an estimated risk 
of 0.19 indicating that the decision tree is able to correctly 
classify 81% of data variability.
The decision tree presented above did not take into 
consideration the disability grade upon admission. When 
the initial disability grade was added to the multivariate 
analysis, only this variable remained in the final model. 
The decision tree that includes this variable shows the 
Table 4 - Univariate analysis of the association between age, number of affected nerves, bacteriological index and disability grade 
upon release from multidrug treatment (MDT) in 255 new cases of leprosy reported at Eduardo de Menezes Hospital, 2005-2010. 
Grade 0 Grade 1 Grade 2 p-value
Age
     Mean 
     Standard deviation 
     Minimum 
     Maximum 
     25th percentile 
     Median 
     75th percentile
41.5 
15.9 
3.0 
77.0 
31.3 
41.5 
52.8
50.9 
15.7 
12.0 
83.0 
40.0 
54.0 
61.0
50.3 
15.8 
18.0 
79.0 
39.8 
49.5 
65.0
<0.001*
Number of affected nerves
     Mean 
     Standard deviation 
     Minimum 
     Maximum 
     25th percentile  
     Median 
     75th percentile
0.6 
1.3 
0.0 
9.0 
0.0 
0.0 
0.0
3.8 
3.1 
0.0 
12.0 
1.0 
3.5 
6.0
8.9 
4.6 
1.0 
18.0 
5.0 
9.5 
12.0
<0.001*
Bacteriological index
     Mean 
     Standard deviation 
     Minimum 
     Maximum 
     25th percentile 
     Median 
     75th percentile
0.9 
1.7 
0.0 
6.0 
0.0 
0.0 
0.8
1.4 
1.7 
0.0 
5.0 
0.0 
0.0 
3.0
1.5 
1.7 
0.0 
5.0 
0.0 
0.5 
3.0
<0.001*
Note: * Kruskal-Wallis test
Table 5 - Factors associated with the disability grade upon release from multidrug treatment (MDT) in the multivariate model, in 
new cases of leprosy reported at Eduardo de Menezes Hospital, 2005-2010.
Variables p-value
Grade 0 x Grade 1 Grade 0 x Grade 2
OR CI 95% OR CI 95%
Sensory impairment <0.001 6.80 [2.68 - 17.24] 45.36 [7.11 - 289.20]
Number of affected nerves 0.031 1.35 [1.08 - 1.68] 1.81 [1.17 - 2.81]
Note: Deviance = 120.75 (p-value = 0.999)OR: odds ratio CI: confidence interval
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progression of the disability grade from diagnosis to the 
end of treatment (Figure 2). Patients with grade 1 disability 
upon admission presented a 10.7% probability of evolving 
to grade 2 upon release from MDT, whereas patients 
already admitted with grade 2 disabilities have a 95.2% 
probability of remaining the same by the end of treatment. 
No patients admitted with grade 0 evolved to grade 2 upon 
release from MDT. 
DISCUSSION
The factors associated with physical disabilities upon 
release from MDT were the number of affected nerves, 
sensory impairment, and, primarily, the presence of 
physical disability upon diagnosis. A multivariate analysis 
using ordinal logistic regression showed that the risk of 
physical disability upon release from MDT progressively 
increases with an increasing number of affected nerves 
upon admission. For each affected nerve presented upon 
admission, the chance of presenting grade 1 disability at 
the end of treatment increased by 1.35 fold, while the risk 
of having grade 2 disability increased by 1.81 fold. Ordinal 
logistic regression also showed that the presence of sensory 
impairment upon diagnosis increased by almost seven 
times the chance of presenting grade 1 disability and by 
45 times the chance of presenting grade 2 disability upon 
release from MDT.
The multivariate analysis, using the CART algorithm, 
showed similar risk factors and supported the findings from 
ordinal logistic regression. It also enabled the development 
of a decision rule that may have direct applicability in the 
clinical practice of professionals dealing with leprosy. The 
decision tree allows for these professionals to identify 
patients with an increased risk of physical disabilities, and 
who should thus be followed up more carefully. Another 
advantage of the decision tree is that the factors used to 
predict the risk of disability upon release from MDT can 
be assessed with simple and widely available clinical tests 
(nerve palpation, sensory testing and voluntary muscle 
testing). Although promising, the applicability of the 
clinical rule needs to be confirmed by additional research, 
including prospective studies in different populations.
However, when the disability grade upon diagnosis was 
included in the multivariate analysis, only this variable 
Figure 1 - Classification and regression tree for factors associated with the disability grade upon release from multidrug therapy 
(MDT) in new cases of leprosy.
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remained in the final model, which indicates that the 
disability grade upon admission is the main risk factor for 
disability upon release from MDT.
The main limitation of the study is the fact that it is 
retrospective, with the possibility of information bias. The 
development of the present study in a referral hospital 
in Brazil, with high rates of multibacillary cases and 
impairment upon diagnosis, limits the extrapolation of 
results to other contexts, such as basic health units and 
other populations. 
A broad variation was observed in the prevalence of 
nerve function impairment and physical disabilities due to 
leprosy in different studies. One cohort study in Bangladesh 
showed sensory impairment in 11.9% of the cases and 
motor impairment in 7.39%16, while, in a study conducted 
in Nepal, sensory and motor impairment occurred in 29.0 
and 24.0% of cases, respectively17. In the present study, the 
prevalence of nerve function impairment was high. Sensory 
impairment was observed in 38.5% of the cases and motor 
impairment in 20.0%. In relation to the disability grade 
upon diagnosis, the percentage of patients with grade 1 and 
grade 2 was, respectively, 9.6% and 5.9% in Bangladesh16, 
11.0% and 7.3% in Thailand18, 29.1% and 10.1% in Minas 
Gerais10, and 31.0% and 27.0% in Ethiopia19. The present 
study also showed high rates of disability upon diagnosis 
(21.5% of grade 1 and 16.2% of grade 2), even though 
these rates were still lower than those reported in Ethiopia. 
Differences in the prevalence of nerve function impairment 
and physical disability could be explained by several factors, 
including differences in patient selection criteria, in the 
proportion of MB cases in the population, in the disability 
grading system used, and in the nerve function assessment. 
Studies that assess tactile sensations using a ballpoint pen, 
as is the case of cohorts in Bangladesh and Thailand, could 
underestimate the prevalence of sensory impairment16,18 .
The proportion of new cases with grade 2 disability 
upon diagnosis among all new cases detected during the 
year is used as an indicator of the quality of case detection 
activities. Percentages equal to or greater than 10% are 
considered high12. In Brazil, there was an increase in the 
proportion of new cases detected with grade 2 disabilities 
from 7.5% in 2015 to 8,3% in 201720. The high prevalence 
of grade 2 disability upon admission in the present study 
(16.2%) could be related to the fact that it was conducted in 
a referral center which deals with high complexity cases, as 
well as to the delay in diagnosis, due to the lack of awareness 
of the early warning signs of disease and the low capacity 
of basic health care units to recognize and treat leprosy as 
early as possible. 
The multivariate analysis findings support previous 
studies showing that the number of affected nerves and 
the presence of nerve function impairment upon diagnosis 
were associated with physical disabilities. In a Nepalese 
study, the presence of more than three enlarged nerves 
increased the chance of impairment by 3.3 fold17, while a 
cohort study in India showed that the presence of more than 
four enlarged nerves increased the risk of impairment by 
1.2 fold9. A retrospective study in Belo Horizonte, Minas 
Figure 2 - Classification and regression tree that shows the progression of the disability grade from diagnosis to the release from 
treatmentin new cases of leprosy. 
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Gerais State, Brazil, showed that the chance of disability 
was 10 times higher for patients with three or more affected 
nerves21, a cohort in India showed that the presence of 
palmo-plantar anesthesia upon diagnosis increased the 
chance of disability at the end of treatment by 2.4 fold22. 
In a study from Bangladesh, risk factors for nerve function 
impairment during two years of follow-up included MB 
classification, the presence of one or more enlarged nerves, 
and primarily, nerve function impairment upon diagnosis 
(hazard ratio of 7.4)23.
Few studies in the literature have used CART algorithms 
to analyze risk factors for disability in leprosy. In a 
retrospective study conducted in a basic health care unit 
in Belo Horizonte, Minas Gerais State, Brazil, the factors 
associated with progression in the disability grade, in a 
multivariate analysis using the decision tree included: 
disability grade upon admission, type of physiotherapy 
treatment, dose of steroids, age, number of affected nerves 
and occurrence of leprosy reactions21.
The present study showed that the disability grade 
upon admission is the main risk factor for disability upon 
release from MDT. Other studies have similar findings. 
A retrospective study in Bangladesh showed that only 
1.6% of the PB and 7.9% of the MB patients without 
initial disabilities presented nerve function impairment 
during the period of treatment24. A cohort study conducted 
in Ethiopia, with 592 new leprosy cases, compared 
the maximum grade of disability and the eye-hand-
foot impairment score (EHF score) at three moments: 
admission, release from treatment and between 24 and 
48 months after release from MDT. Overall, the EHF 
score distributions did not change significantly over time25. 
The Ethiopian cohort study demonstrated that the initial 
disability grade is still the main prognostic factor even 
five years after release from treatment. Patients with initial 
EHF scores of 1 or 2 had a relative risk of 9.1, whereas 
patients with scores equal to or higher than 3 presented 
65 times higher risk of disability five years after release 
from MDT26.
CONCLUSION
The findings of the present study corroborate those 
of previous studies developed in different countries, 
demonstrating that risk factors for disabilities in Brazil 
are similar to the ones found in other populations. Thus, 
strategies to reduce the prevalence of disabilities could 
be developed globally, with contributions from all highly 
endemic countries.
The present study reinforces that the greater the 
disability grade upon admission, the higher the probability 
of disability upon release from MDT. It is known that the 
presence of disability upon admission is an important 
indicator of delay in diagnosis. Therefore, this study 
emphasizes the great importance of early detection and 
treatment of leprosy to prevent disabilities and deformities. 
The major impact of this study in the clinical practice 
is the development of a clinical score that can be used to 
predict the risk of disability at the end of treatment. The 
decision tree is based on simple clinical tests, which are 
available worldwide with no additional costs and can 
be applied in a wide range of health services. It may be 
useful in other settings, but it must be externally validated 
before its application can be scientifically justified in other 
populations. Nonetheless, we expect that patients in other 
settings will behave similarly since the risk factors for 
physical disabilities are similar, as are the almost universal 
methods of nerve-function assessment and treatment 
in leprosy. Additional research, including prospective 
studies in different populations, is required to confirm the 
applicability of the decision tree in daily practice.
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